Researchers took advantage of a modified rabies virus vector, and incorporated a gene from Nipah virus - creating a viral particle that displays components of both viruses on its surface.
Researchers made two versions of a potential vaccine and evaluated their effectiveness and safety in mice that were genetically altered to have more human-like immune responses. After the mice were vaccinated and then infected with Middle East respiratory syndrome (MERS), both vaccines protected the mice against clinical signs of disease and death.
The Department of Homeland Security Science and Technology Directorate (S&T) has been intensifying African swine fever (ASF) vaccine research efforts since November in collaboration with the USDA. The African Swine Fever Task Force was created, based out of S&T’s Plum Island Animal Disease Center (PIADC), to tackle this threat to the swine industry.
Intradermal administration of a DNA Ebola vaccine candidate using electroporation showed improvements over intramuscular administration in a recent study that found the new approach to Ebola prevention to be well-tolerated and effective.
The US government's Biomedical Advanced Research and Development Authority (BARDA) has awarded a $10 million contract to a Massachusetts-based biotech firm to work on a vaccine for Marburg virus.
As the list of candidates for a Lassa fever vaccine grows, a consistent set of challenges is emerging.
To increase national health security against biothreats and protect public health, the US Department of Health and Human Services (HHS) will partner with Public Health Vaccines LLC of Cambridge, Massachusetts, to develop a potential vaccine against Marburg virus. No licensed vaccine for this virus exists today.
Research found that vaccination with an adjuvanted Middle East respiratory syndrome (MERS) Spike protein subunit vaccine confers complete protection from MERS disease in alpaca and results in reduced and delayed viral shedding in the upper airways of dromedary camels. Together, these data indicate that induction of robust neutralizing humoral immune responses by vaccination of naïve animals reduces shedding that potentially could diminish the risk of zoonotic transmission.
A global coalition set up to fight emerging epidemics has struck a $31 million deal with scientists at the University of Tokyo to speed up work on a vaccine against Nipah virus.
A novel, synthetic DNA vaccine developed at the Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South America, that has the potential to become a global emerging viral threat.